Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.6.2651

Elevated Serum Neutrophil to Lymphocyte and Platelet to Lymphocyte Ratios Could be Useful in Lung Cancer Diagnosis  

Kemal, Yasemin (Department of Medical Oncology, Faculty of Medicine, 19 Mayis Univercity)
Yucel, Idris (Department of Medical Oncology, Faculty of Medicine, 19 Mayis Univercity)
Ekiz, Kubilay (Department of Internal Medicine, Faculty of Medicine, 19 Mayis Univercity)
Demirag, Guzin (Department of Medical Oncology, Faculty of Medicine, 19 Mayis Univercity)
Yilmaz, Bahiddin (Department of Medical Oncology, Faculty of Medicine, 19 Mayis Univercity)
Teker, Fatih (Department of Medical Oncology, Faculty of Medicine, 19 Mayis Univercity)
Ozdemir, Meltem (Department of Internal Medicine, Faculty of Medicine, 19 Mayis Univercity)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.6, 2014 , pp. 2651-2654 More about this Journal
Abstract
Background: Lung cancer (LC) is still the primary cause of cancer deaths worldwide, and late diagnosis is a major obstacle to improving lung cancer outcomes. Recently, elevated preoperative or pretreatment neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and mean platelet volume (MPV) detected in peripheral blood were identified as independent prognostic factors associated with poor survival with various cancers, including colon cancer, esophageal cancer, gastric cancer and breast cancer. Objective: The aim of this study was to examine whether MPV, NLR and PLR could be useful inflammatory markers to differentiate lung cancer patients from healthy controls. An investigation was also made of the relationship between these markers and other prognostic factors and histopathological subgroups. Materials and Methods: Retrospectively eighty-one lung cancer patients and 81 age-sexes matched healthy subjects included into the study. Patients with hypertension, hematological and renal disease, heart failure, chronic infection, hepatic disorder and other cancer were excluded from the study. The preoperative or pretreatment blood count data was obtained from the recorded computerized database. Results: NLR and PLR values were significantly higher in the LC patients compared to the healthy subjects.( NLR: 4.42 vs 2.45 p=0.001, PLR: 245.1 vs 148.2 p=0.002) MPV values were similar in both groups (7.7 vs 7.8). No statistically significant relationship was determined between these markers (MPV, NLR and PLR) and histopathological subgroups and TNM stages. Conclusions: NLR and PLR can be useful biomarkers in LC patients before treatment. Larger prospective studies are required to confirm these findings.
Keywords
Lung cancer; platelets; neutrophils; lymphocytes; ratios;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A (2013). Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac J Cancer Prev, 14, 5237-42.   DOI   ScienceOn
2 Suzuki K, Kachala SS, Kadota K et al (2011). Prognostic immune markers in non-small cell lung cancer. Clin Cancer Res, 17, 5247-56.   DOI   ScienceOn
3 Thavaramara T, Phaloprakarn C, Tangjitgamol S et al (2011). Role of neutrophil to lymphocyte ratio as a prognostic indicator for epithelial ovarian cancer. J Med Assoc Thai, 94, 871-7.
4 Walsh SR, Cook EJ, Goulder F et al (2005). Neutrophillymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol, 91, 181-4.   DOI   ScienceOn
5 Wiesner T, Bugl S, Mayer F, et al (2010). Differential changes in platelet VEGF, Tsp, CXCL12, and CXCL4 in patients with metastatic cancer. Clin Exp Metastasis, 27, 141-9.   DOI
6 Ohashi R, Takahashi K, Miura K et al (2006). Prognostic factors in patients with inoperable non-small cell lung cancer-an analysis of long-term survival patients. Gan To Kagaku Ryoho, 33, 1595-602.
7 Lee Y, Kim SH, Han JY, et al (2012). Early neutrophil-tolymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. J Cancer Res Clin Oncol, 138, 2009-16.   DOI   ScienceOn
8 Mangalpally KK, Siqueiros-Garcia A, Vaduganathan M (2010). Platelet activation patterns in plateletsize sub-populations: differential responses to aspirin in vitro. J Thromb Thrombolysis, 30, 251-62.   DOI
9 Mantovani A, Allavena P, Sica A, Ballkwill F (2008). Cancerrelated inflammation. Nature, 454, 436-44   DOI   ScienceOn
10 Petrie HT, Klassen LW, Kay HD(1985). Inhibition of human Cytotoxic T lymphocyte activity in vitro By autologous peripheral blood granulocytes. J Immunol, 134, 230-4.
11 Sandler A, Gray R, Perry M, et al (2006). Paclitaxel-carboplatin alone or with bevacizumab in non-small cell lung cancer. NEJM, 355, 2542-50.   DOI   ScienceOn
12 Holmes CE, Levis JE, Ornstein DL (2009). Activated platelets enhance ovarian cell invasion in a cellular model of metastasis. Clin Exp Metastasis, 26, 653-61.   DOI
13 Schreiber RD, Old LJ, Smyth MJ (2011). Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science, 331, 1565-70.   DOI   ScienceOn
14 Sharaiha RZ, Halazun KJ, Mirza F, et al (2011). Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol, 18, 3362-9.   DOI   ScienceOn
15 Smith R, Bosonnet L, Raraty M, et al (2009). Preoperative plateletlymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg, 197, 466-72.   DOI   ScienceOn
16 Groome PA, Bolejack V, Crowley JJ et al (2007). The IASLC Lung Cancer Staging Project: validation of the proposal for revision of the T, N and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumors. J Thorac Oncol, 2, 694-705.   DOI
17 Gwak MS, Choi SJ, Kim JA et al (2007). Effects of gender on white blood cell populations and neutrophil-lymphocyte ratio following gastrectomy in patients with stomach cancer. J Korean Med, 22, 104-8.   DOI   ScienceOn
18 Howlader N, Noone AM, Krapcho M, et al (2009). SEER Cancer Statistics Review 1975-2009 (Vintage: Populations), Bethesda, MD, National Cancer Institute.
19 Jemal A, Bray F, Center MM et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.   DOI
20 Kai H, Kitadai Y, Kodama M Cho S, Kuroda T, Ito M et al (2005). Involvement of proinflammatory cytokinesIL-1beta and IL-6 in progression of human gastric carcinoma. Anticancer Res, 25, 709-13.
21 Balkwill F, Mantovani A (2001). Inflammation and cancer: back toVirchow? Lancet, 357, 539-45.   DOI   ScienceOn
22 Kaya V, Yildirim M, Demirpence O, Yildiz M, Yalcin AY (2013). Prognostic significance of basic laboratory methods in nonsmall- cell-lung cancer. Asian Pac J Cancer Prev, 14, 5473-6.   DOI   ScienceOn
23 Kilincalp S, Ekiz F, Basar O, et al (2013). Platelet volume could be possible biomarker in early diagnosis and monitoring of gastric cancer. Platelets, [Epub ahead of print].
24 Azab B, Bhatt VR, Phookan J et al (2012). Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol, 19, 217-24.   DOI   ScienceOn
25 Bambace NM, Holmes CE (2011). The platelet contribution to cancer progression. J Thromb Haemost, 9, 237-49.   DOI   ScienceOn
26 Benoy I, Salgado R, Colpaert C, et al (2002). Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer, 2, 311-5.   DOI   ScienceOn
27 De Larco JE, Wuertz BRK, Furcht LT (2004). The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res, 10, 4895-900.   DOI   ScienceOn
28 Donnem T, Bremnes RM, Busund LT et al (2012). Gene expression assays as prognostic and predictive markers in early stage non-small cell lung cancer. J Thorac Dis, 4, 212-3.
29 Dvorak HF, Brown LF, Detmar M, et al(1995).Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol, 146, 1029-39.
30 Fidler IJ (2003). The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer, 3, 453-8.   DOI   ScienceOn
31 Hoang T, Xu R, Schiller JH et al (2005). Clinical model to predict survival in chemo-naive patients with advanced non-small cell lung cancer treated with third generation chemotherapy regimen based on eastern cooperative oncology group data. J Clin Oncol, 23, 175-83.   DOI   ScienceOn
32 Tanner NT, Sherman CA, Silvestri GA (2012). Biomarkers in the selection of maintenance therapy in nonsmall cell lung cancer. Transl Lung Cancer Res, 1, 96-8.